gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Dec 2016.

TOX high mobility group box family member 3

TNRC9, TOX3, trinucleotide repeat containing 9
The protein encoded by this gene contains an HMG-box, indicating that it may be involved in bending and unwinding of DNA and alteration of chromatin structure. The C-terminus of the encoded protein is glutamine-rich due to CAG repeats in the coding sequence. A minor allele of this gene has been implicated in an elevated risk of breast cancer. Two transcript variants encoding different isoforms have been found for this gene.[provided by RefSeq, Apr 2009] (from NCBI)
Top mentioned proteins: FGFR2, LSP1, Iris, AGE, HAD
Papers on TNRC9
Prevalence and Determinants of Periodic Limb Movements in the General Population.
Heinzer et al., Lausanne, Switzerland. In Ann Neurol, Jan 2016
Single nucleotide polymorphisms (SNP) within BTBD9 (rs3923809), TOX3 (rs3104788) and MEIS1 (rs2300478) genes were significantly associated with PLSMI>15/h.
Susceptible genes of restless legs syndrome in migraine.
Wang et al., Taipei, Taiwan. In Cephalalgia, Jan 2016
METHODS: Thirteen single-nucleotide polymorphisms (SNPs) at six RLS risk loci (MEIS1, BTBD9, MAP2K5, PTPRD, TOX3, and an intergenic region on chromosome 2p14) were genotyped in 211 migraine patients with RLS and 781 migraine patients without RLS.
Association of polymorphisms with a family history of cancer and the presence of germline mutations in the BRCA1/BRCA2 genes.
Palmero et al., Barretos, Brazil. In Hered Cancer Clin Pract, Dec 2015
The constitutive DNA was analyzed for the presence of polymorphisms at rs2981582 (FGFR2 gene); rs3803662 (TNRC9); rs889312 (MAP3K1); rs3817198 (LSP1 gene); and rs13281615 (8q24).
Association of low ferritin with PLM in the Wisconsin Sleep Cohort.
Mignot et al., Palo Alto, United States. In Sleep Med, Nov 2015
Analyses were performed using a linear model with PLM category above and below 15 PLM/h (periodic leg movement index, PLMI) as the dependent variable, and adjusting for known covariates, including previously associated single-nucleotide polymorphisms (SNPs) within BTBD9, TOX3/BC034767, MEIS1, MAP2K5/SKOR1, and PTPRD.
[Associations between TOX3 rs3803662 polymorphisms and immunological markers of breast cancer].
Xu et al., Zhengzhou, China. In Zhonghua Yi Xue Za Zhi, Oct 2015
OBJECTIVE: TOX3 gene was considered to be breast cancer susceptibility gene in the European population and East Asian populations.
Genetic susceptibility to triple-negative breast cancer.
Couch et al., Rochester, United States. In Cancer Res, 2013
Common variation in a subset of the 72 known breast cancer susceptibility loci identified through genome-wide association studies and other large-scale genotyping efforts have also been associated with risk of TNBC (TOX3, ESR1, RAD51L1, TERT, 19p13.1,
Breast cancer risk-associated SNPs modulate the affinity of chromatin for FOXA1 and alter gene expression.
Lupien et al., United States. In Nat Genet, 2012
Furthermore, the majority of the risk-associated SNPs modulate the affinity of chromatin for FOXA1 at distal regulatory elements, thereby resulting in allele-specific gene expression, which is exemplified by the effect of the rs4784227 SNP on the TOX3 gene within the 16q12.1 risk locus.
Genome-wide association study identifies a common variant in RAD51B associated with male breast cancer risk.
Swerdlow et al., London, United Kingdom. In Nat Genet, 2012
We also refine association at 16q12.1 to a SNP within TOX3 (P = 3.87 × 10(-15); OR = 1.50).
Breast cancer genome-wide association studies: there is strength in numbers.
Russo et al., Palermo, Italy. In Oncogene, 2012
Recently, genome wide association studies (GWAS) in BC revealed single nucleotide polymorphisms (SNPs) in five novel genes associated to susceptibility: TNRC9, FGFR2, MAP3K1, H19 and lymphocyte-specific protein 1 (LSP1).
Differential epigenetic regulation of TOX subfamily high mobility group box genes in lung and breast cancers.
Belinsky et al., Albuquerque, United States. In Plos One, 2011
Compared with TOX4, expression of TOX1, TOX2 and TOX3 in normal lung was 25, 44, and 88%lower, respectively, supporting the premise that reduced promoter activity confers increased susceptibility to methylation during lung carcinogenesis.
Genetic polymorphisms and breast cancer risk: evidence from meta-analyses, pooled analyses, and genome-wide association studies.
Lai et al., China. In Breast Cancer Res Treat, 2011
Of the 25 SNPs, 20 were noteworthy: C6orf97 (rs2046210 and rs3757318), FGFR2 (rs2981579, rs1219648, and rs2981582), LSP1 (rs909116), RNF146 (rs2180341), SLC4A7 (rs4973768), MRPS30 (rs7716600), TOX3 (rs3803662 and rs4784227), ZNF365 (rs10995190), rs889312, rs614367, rs13281615, rs13387042, rs11249433, rs1011970, rs614367, and rs1562430.
Association between polymorphisms of trinucleotide repeat containing 9 gene and breast cancer risk: evidence from 62,005 subjects.
Lu et al., Kunshan, China. In Breast Cancer Res Treat, 2011
Polymorphisms of trinucleotide repeat containing 9 gene is associated with breast cancer.
TOX3 is a neuronal survival factor that induces transcription depending on the presence of CITED1 or phosphorylated CREB in the transcriptionally active complex.
Methner et al., Düsseldorf, Germany. In J Cell Sci, 2011
TOX3 induces transcription in neuron depending on the presence of CITED1 or phosphorylated CREB in the transcriptionally active complex.
Incidence of breast cancer and its subtypes in relation to individual and multiple low-penetrance genetic susceptibility loci.
Million Women Study Collaborators et al., Oxford, United Kingdom. In Jama, 2010
findings strengthen the existing evidence that FGFR2-rs2981582 and TNRC9-rs3803662 are predominantly associated with ER-positive breast cancer
Gene-environment interactions in 7610 women with breast cancer: prospective evidence from the Million Women Study.
Million Women Study Collaborators et al., Oxford, United Kingdom. In Lancet, 2010
METHODS: We tested gene-environment interactions in 7610 women who developed breast cancer and 10 196 controls without the disease, studying the effects of 12 polymorphisms (FGFR2-rs2981582, TNRC9-rs3803662, 2q35-rs13387042, MAP3K1-rs889312, 8q24-rs13281615, 2p-rs4666451, 5p12-rs981782, CASP8-rs1045485, LSP1-rs3817198, 5q-rs30099, TGFB1-rs1982073, and ATM-rs1800054) in relation to prospectively collected information about ten established environmental risk factors (age at menarche, parity, age at first birth, breastfeeding, menopausal status, age at menopause, use of hormone replacement therapy, body-mass index, height, and alcohol consumption).
Polymorphisms in the TOX3/LOC643714 locus and risk of breast cancer in African-American women.
Palmer et al., Boston, United States. In Cancer Epidemiol Biomarkers Prev, 2010
Single nucleotide polymorphism in TOX3 is associated with breast cancer.
Breast cancer susceptibility: current knowledge and implications for genetic counselling.
Schlegelberger et al., Hannover, Germany. In Eur J Hum Genet, 2009
Although candidate gene approaches demonstrated moderately increased breast cancer risks for rare mutations in genes involved in DNA repair (ATM, CHEK2, BRIP1, PALB2 and RAD50), genome-wide association studies identified several SNPs as low-penetrance breast cancer susceptibility polymorphisms within genes as well as in chromosomal loci with no known genes (FGFR2, TOX3, LSP1, MAP3K1, TGFB1, 2q35 and 8q).
Genetic susceptibility loci for breast cancer by estrogen receptor status.
Chanock et al., Rockville, United States. In Clin Cancer Res, 2009
Recent work from large consortial studies has led to the discovery of novel breast cancer susceptibility loci in genic (CASP8, FGFR2, TNRC9, MAP3K1, LSP1) and nongenic regions (8q24, 2q35, 5p12) of the genome, and to the finding of substantial heterogeneity by tumor characteristics.
Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer.
Stefansson et al., Reykjavík, Iceland. In Nat Genet, 2007
rs3803662 is near the 5' end of TNRC9 , a high mobility group chromatin-associated protein whose expression is implicated in breast cancer metastasis to bone.
share on facebooktweetadd +1mail to friends